Literature DB >> 28550507

Histopathologic Features are more Important Prognostic Factors than Primary Tumour Location in Gastro-oesophageal Adenocarcinoma Treated with Preoperative Chemoradiation and Surgery.

Milan Vošmik1, Jan Laco2, Igor Sirák3, Josef Dvořák3, Petr Lochman4,5, Miroslav Hodek3, Petra Malá3, Stanislav Rejchrt6, Rudolf Repák6, Michal Leško5, Alexander Ferko5, Aleš Ryška2, Bohuslav Melichar7, Jiří Petera3.   

Abstract

The aim of present study was to evaluate the impact of primary tumour location and other factors on the outcome of preoperative chemoradiation followed by surgery in adenocarcinomas of distal oesophagus, gastro-oesophageal junction and stomach. We retrospectively reviewed the institutional patient database. The therapeutic response was re-evaluated as a percentage of residual tumor cells in surgical resection specimens. Overall survival (OS) and disease-free survival (DFS) were assessed. The effect primary tumour location, clinical and pathological TNM stage, and histopathological factors (histological type, grade, angioinvasion, perineural invasion, tumour response) on treatment outcome were evaluated. A total of 108 patients underwent preoperative chemoradiation for adenocarcinoma of distal oesophagus, gastro-oesophageal junction or stomach. The median prescribed dose of radiation was 45 Gy. The concurrent chemotherapy consisted of 5-fluorouracil +/- cisplatin +/- taxanes. R0 resection was achieved in 80 patients (74%). The complete response was observed in 19%. The median follow-up was 50.8 months. Three-year and 5-year OS and DFS were 36.2% and 25.3%; and 28.1% and 23.7%, respectively. Pretreatment T-stage, pathological N-stage, radicality of resection, histological subtype, grade, angioinvasion and perineural invasion, were identified as statistical significant OS predictors in univariate analysis; pathological N-stage, radicality of resection and angioinvasion, in multivariate analysis. The primary tumor location did not influence the prognosis. The pathologic response to chemoradiation had borderline significance. In conclusion, no prognostic impact of primary tumour location, in contrast to other investigated factors, was evident in the present study. The most important predictors of prognosis were angioinvasion status and pN-stage.

Entities:  

Keywords:  Distal oesophageal cancer; Gastric cancer; Gastro-oesophageal junction cancer; Preoperative chemoradiation; Prognostic factor

Mesh:

Year:  2017        PMID: 28550507     DOI: 10.1007/s12253-017-0253-z

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  30 in total

1.  A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer.

Authors:  John D Urschel; Hari Vasan
Journal:  Am J Surg       Date:  2003-06       Impact factor: 2.565

2.  Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma.

Authors:  Pooja R Rohatgi; Paul F Mansfield; Christopher H Crane; Tsung-Teh Wu; Punita K Sunder; William A Ross; Jeffrey S Morris; Peter W Pisters; Barry W Feig; Leonard L Gunderson; Jaffer A Ajani
Journal:  Cancer       Date:  2006-10-01       Impact factor: 6.860

3.  Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy.

Authors:  Brian Badgwell; Mariela Blum; Jeannelyn Estrella; Yi-Ju Chiang; Prajnan Das; Aurelio Matamoros; Keith Fournier; Paul Mansfield; Jaffer Ajani
Journal:  J Am Coll Surg       Date:  2015-04-15       Impact factor: 6.113

4.  Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma.

Authors:  Twisha Chakravarty; Christopher H Crane; Jaffer A Ajani; Paul F Mansfield; Tina M Briere; A Sam Beddar; Henry Mok; Valerie K Reed; Sunil Krishnan; Marc E Delclos; Prajnan Das
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-12-02       Impact factor: 7.038

5.  A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.

Authors:  T N Walsh; N Noonan; D Hollywood; A Kelly; N Keeling; T P Hennessy
Journal:  N Engl J Med       Date:  1996-08-15       Impact factor: 91.245

Review 6.  Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis.

Authors:  F Fiorica; D Di Bona; F Schepis; A Licata; L Shahied; A Venturi; A M Falchi; A Craxì; C Cammà
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

7.  Epidermal growth factor receptor as a predictor of tumor response to preoperative chemoradiation in locally advanced gastric carcinoma.

Authors:  Igor Sirak; Jiri Petera; Jana Hatlova; Milan Vosmik; Bohuslav Melichar; Josef Dvorak; Zdenek Zoul; Vera Tycova; Michal Lesko; Marian Hajduch
Journal:  Strahlenther Onkol       Date:  2008-11-19       Impact factor: 3.621

8.  Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma-a pilot study.

Authors:  M Orditura; G Galizia; N Di Martino; E Ancona; C Castoro; R Pacelli; F Morgillo; S Rossetti; V Gambardella; A Farella; M M Laterza; A Ruol; A Fabozzi; V Napolitano; F Iovino; E Lieto; L Fei; G Conzo; F Ciardiello; F De Vita
Journal:  Curr Oncol       Date:  2014-06       Impact factor: 3.677

9.  TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG).

Authors:  Trevor Leong; B Mark Smithers; Michael Michael; Val Gebski; Alex Boussioutas; Danielle Miller; John Simes; John Zalcberg; Karin Haustermans; Florian Lordick; Christoph Schuhmacher; Carol Swallow; Gail Darling; Rebecca Wong
Journal:  BMC Cancer       Date:  2015-07-21       Impact factor: 4.430

10.  Preoperative chemoradiotherapy for locally advanced gastric cancer.

Authors:  Joseph M Pepek; Junzo P Chino; Christopher G Willett; Manisha Palta; Dan G Blazer Iii; Douglas S Tyler; Hope E Uronis; Brian G Czito
Journal:  Radiat Oncol       Date:  2013-01-04       Impact factor: 3.481

View more
  4 in total

1.  The Impact of Tumor Regression on Prognosis After Neoadjuvant Chemoradiotherapy in Surgically Treated Esophageal Adenocarcinoma.

Authors:  D J Crull; M C H Hogenes; R Hoekstra; E M Hendriksen; M J van Det; E A Kouwenhoven
Journal:  Ann Surg Oncol       Date:  2022-01-29       Impact factor: 5.344

2.  The effect of histologic grade on neoadjuvant treatment outcomes in esophageal cancer.

Authors:  David T Pointer; Jordan A McDonald; Samer A Naffouje; Rutika Mehta; Jason B Fleming; Jacques P Fontaine; Gregory Y Lauwers; Jessica M Frakes; Sarah E Hoffe; Jose M Pimiento
Journal:  J Surg Oncol       Date:  2022-05-16       Impact factor: 2.885

3.  Modified ypTNM Staging Classification for Gastric Cancer after Neoadjuvant Therapy: A Multi-Institutional Study.

Authors:  Qing Zhong; Qi-Yue Chen; Amilcare Parisi; Yu-Bin Ma; Guang-Tan Lin; Jacopo Desiderio; Su Yan; Jian-Wei Xie; Jia-Bin Wang; Jun-Fang Hou; Jian-Xian Lin; Jun Lu; Long-Long Cao; Mi Lin; Ru-Hong Tu; Ze-Ning Huang; Ju-Li Lin; Zhi-Yu Liu; Si-Jin Que; Ping Li; Chao-Hui Zheng; Chang-Ming Huang
Journal:  Oncologist       Date:  2020-09-17

4.  ASO Author Reflections: Improvement of Esophageal Cancer Staging by Implementing Mandard Tumor Regression Score.

Authors:  D J Crull; M C H Hogenes; R Hoekstra; E M Hendriksen; M J van Det; E A Kouwenhoven
Journal:  Ann Surg Oncol       Date:  2022-01-19       Impact factor: 5.344

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.